B. Vrijens, G. Vincze, P. Kristanto, J. Urquhart and M. Burnier, “Adherence to Prescribed Antihypertensive Drug Treatments: Longitudinal Study of Electronically Compiled Dosing Histories,” British Medical Journal, Vol. 336, No. 7653, 2008, pp. 1114-1117.
 P. Girard, L. B. Sheiner, H. Kastrissios and T. F. Blaschke, “Do we Need Full Compliance Data for Population Pharmacokinetic Analysis?” J Pharmacokinetics and Biopharmaceutics, Vol. 24, No. 3, 1996, pp. 265-282.
 A. Blesius, S. Chabaud, M. Cucherat, P. Mismetti, J. P. Boissel and P. Nony, “Compliance-Guided Therapy: A New Insight into the Potential Role of Clinical Pharmacologists,” Clinical Pharmacokinetics, Vol. 45, No. 1, 2006, pp. 95-104.
 J. Li and F. Nekka, “A Probabilistic Approach for the Evaluation of Pharmacological Effect Induced by Patient Irregular Drug Intake,” Journal of Pharmacokinetics and Pharmacodynamics, Vol. 36, No. 3, 2009, pp. 221-238.
 B. Vrijens, E. Goetghebeur, E. de Klerk, R. Rode, S. Mayer and J. Urquhart, “Modelling the Association between Adherence and Viral Load in HIV-Infected Patients,” Statistics in Medicine, Vol. 24, No. 17, 2005, pp. 2719-2131.
 Y. Huang, S. L. Rosenkranz and H. Wu, “Modeling HIV Dynamics and Antiviral Response with Consideration of Time-Varying Drug Exposures, Adherence and Phenotypic Sensitivity,” Mathematical Biosciences, Vol. 184, No. 2, 2003, pp. 165-186.
 E. Hénin, B. You, B. Tranchand, G. Freyer and P. Girard, “Issues of the Study of Patient Compliance to Treatment with Oral Anticancer Chemotherapy: Advantages of Phar- macokinetics-Pharmacodynamics Modelisation,” Therapie, Vol. 62, No. 2, 2007, pp. 77-85.
 J. Li, C. E. Petit-Jetté, D. Gohore Bi, F. Fenneteau, R. J. Del Castillo and F. Nekka, “Assessing Pharmacokinetic Variability Directly Induced by Drug Intake Behaviour through Development of a Feeding Behaviour-Pharma- cokinetic Model,” Journal of Theoretical Biology, Vol. 251, No. 3, 2008, pp. 468-479.
 F. Fenneteau, J. Li and F. Nekka, “Assessing Drug Distribution in Tissues Expressing P-Glycoprotein Using Physiologically Based Pharmacokinetic Modeling: Identification of Important Model Parameters through Global Sensitivity Analysis,” Journal of Pharmacokinetics and Pharmacodynamics, Vol. 36, No. 6, 2009, pp. 495-522.
 F. Fenneteau, P. Poulin and F. Nekka, “Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates,” Journal of Pharmaceutical Sciences, Vol. 99, No. 1, 2010, pp. 486-514.
 J. Zàdor, I. G. Zsély, T. Turanyi, M. Ratto, S. Tarantola and A. Saltelli, “Local and Global Uncertainty Analyses of a Methane Flame Model,” Journal of Physical Chemistry A, Vol. 109, No. 43, 2005, pp. 9795-9807.
 J. Sun, H. N. Nagaraj, N. R. Reynolds, “Discrete Stochastic Models for Compliance Analysis Based on an AIDS Clinical Trial Group (ACTG) Study,” Biomedicine Journal, 2007, Vol. 49, No. 5, pp. 731-741.
 S. Shimada, Y. Nakajima, K. Yamamoto, Y. Sawada and T. Iga, “Comparative Pharmacodynamics of Eight Calcium Channel Blocking Agents in Japanese Essential Hypertensive Patients,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 3, 1996, pp. 430-437.
 K. Yao, K. Nagashima and H. Miki, “Pharmacological, Pharmacokinetic, and Clinical Properties of Benidipine Hydrochloride, a Novel, Long-Acting Calcium Channel Blocker,” Journal of Pharmacological Sciences, Vol. 100, No. 4, 2006, pp. 243-261.
 H. Y. Yun, M. H. Yun, W. Kang and K. I. Kwon, “Pharmacokinetics and Pharmacodynamics of Benidipine Using a Slow Receptor-Binding Model,” Journal of Clinical Pharmacy and Therapeutics, Vol. 30, No. 6, 2005, pp. 541-547.
 Y. Nakajima, K. Yamamoto, S. Shimada, H. Kotaki, Y. Sawada and T. Iga, “In Vitro-in Vivo Correlation of Pharmacodynamics of Felodipine in Essential Hypertensive Patients Based on an Ion-Channel Binding Model,” Biological and Pharmaceutical Bulletin, Vol. 19, No. 8, 1996, pp. 1097-1099.
 O. Nakajima, H. Akioka and M. Miyazaki, “Effect of the Calcium Antagonist Benidipine Hydrochloride on 24-h Ambulatory Blood Pressure in Patients with Mild to Moderate Hypertension in a Double-Blind Study against Placebo,” Arzneimittelforschung, Vol. 50, No. 7, 2000, pp. 620-625.
 G. Mancia, S. Omboni, E. Agabiti-Rosei, R. Casati, R. Fogari, G. Leonetti, et al., “Antihypertensive Efficacy of Manidipine and Enalapril in Hypertensive Diabetic Patients,” Journal of Cardiovascular Pharmacology, Vol. 35, No. 6, 2000, pp. 926-931.
 S. R. O. Antonicelli, D. C. Giovanni, R. Ansuini, A. Mori, R. Gesuita, G. Parati, et al., “Smooth Blood Pressure Control Obtained with Extended-Release Felodipine in Elderly Patients with Hypertension: Evaluation by 24-Hour Ambulatory Blood Pressure Monitoring,” Drugs Aging, Vol. 19, No. 7, 2002, pp. 541-551.
 G. Mancia, S. Omboni, G. Parati, D. L. Clement, W. E. Haley, S. N. Rahman, et al., “Twenty-Four Hour Ambulatory Blood Pressure in the Hypertension Optimal Treatment (HOT) Study,” Journal of Hypertension, Vol. 19, No. 10, 2001, pp. 1755-1763.
 S. Omboni, R. Fogari and G. Mancia, “A Smooth Blood Pressure Control is Obtained over 24 h by Delapril in Mild to Moderate Essential Hypertensives,” Blood Press, Vol. 10, No. 3, 2001, pp. 170-175.